| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/19/2006 | US20060013818 Method of treating granuloma annulare or sarcoid |
| 01/19/2006 | US20060013817 identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. |
| 01/19/2006 | US20060013816 IgG4 constant region; Fab' fragment; antibody or antigen binding fragment inhibits binding of A2 or cA2 to human TNF- alpha , and binds to a neutralizing epitope of human TNF- alpha |
| 01/19/2006 | US20060013815 Human Mob-5 (IL-24) receptors and uses thereof |
| 01/19/2006 | US20060013813 Proteins and nucleic acids encoding same |
| 01/19/2006 | US20060013812 Mixture comprising blood coagulation factor and serpin for use in prevention and treatment of blood disorders |
| 01/19/2006 | US20060013811 Methods of treating IgE-associated disorders and compositions for use therein |
| 01/19/2006 | US20060013810 Cancer, autoimmune and inflammatory disease, vaccines; binds to the extracellular domain of native human Fc gamma RIIB with greater affinity than to the extracellular domain of native human Fc gamma RIIA |
| 01/19/2006 | US20060013809 Immunotoxin derived from a recombinant human autoantibody and method of using thereof |
| 01/19/2006 | US20060013808 Treatment for asthma |
| 01/19/2006 | US20060013802 Pumping device equipped with catheter; directly delivering interleukin 10 signal transduction modifying agent to cerebrospinal fluid and/or brain tissue |
| 01/19/2006 | US20060013800 Stable immunogenic product comprising antigenic heterocomplexes |
| 01/19/2006 | US20060013773 Diet typing system for humans; diagnosis and treatment of food allergies; presents the results on six diet cards, one for each blood type |
| 01/19/2006 | DE102004025452A1 Vakzine enthaltend BVDV Vaccine containing BVDV |
| 01/19/2006 | CA2577332A1 Combination therapy for the prevention or treatment of alzheimer's disease as well as kit therefor |
| 01/19/2006 | CA2573596A1 S100 protein inhibitors for treating leukemia |
| 01/19/2006 | CA2573505A1 N-glycosylated antibody |
| 01/19/2006 | CA2573424A1 Method for preventing and treating alzheimer´s disease |
| 01/19/2006 | CA2573377A1 Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
| 01/19/2006 | CA2572881A1 Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication |
| 01/19/2006 | CA2572873A1 Inhibitors based on fusion, hr1 and hr2 sequences in bacterial adhesin |
| 01/19/2006 | CA2572509A1 Novel compositions and methods in cancer |
| 01/19/2006 | CA2572334A1 Compositions and methods for modulation of ror.gamma.t |
| 01/19/2006 | CA2572065A1 Immunosuppressive exosomes |
| 01/19/2006 | CA2568526A1 Combination therapy with radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma |
| 01/19/2006 | CA2567808A1 Therapy of platinum-resistant cancer |
| 01/19/2006 | CA2544692A1 Anti-glypican 3 antibody |
| 01/18/2006 | WO2007026190A2 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| 01/18/2006 | EP1617216A1 Novel method of screening |
| 01/18/2006 | EP1616958A2 Notch-ligands for use in immunotherapy |
| 01/18/2006 | EP1616954A2 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 01/18/2006 | EP1616950A1 Peptide having htlv-1-specific ctl-inducing activity |
| 01/18/2006 | EP1616883A2 Antibodies against VLA-4 |
| 01/18/2006 | EP1616882A2 Apo-2 receptor antibodies |
| 01/18/2006 | EP1616881A1 Anti-mpl antibodies |
| 01/18/2006 | EP1616878A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/18/2006 | EP1616877A1 Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
| 01/18/2006 | EP1616876A2 A method for identification, isolation and production of antigens to a specific pathogen |
| 01/18/2006 | EP1616875A1 GD3-mimetic peptides |
| 01/18/2006 | EP1616620A2 Method for coating particles |
| 01/18/2006 | EP1616579A1 CD40 binding molecules and CTL peptides for treating tumors |
| 01/18/2006 | EP1616578A1 Compositions and methods for delivery of genetic material |
| 01/18/2006 | EP1616575A1 Method for treating inflammation |
| 01/18/2006 | EP1616574A1 Receptor specific transepithelial transport of therapeutics |
| 01/18/2006 | EP1616573A2 Adjuvants for use in vaccines |
| 01/18/2006 | EP1616572A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
| 01/18/2006 | EP1616564A2 Manipulation of nitrosative stress for treating microbes and helminths |
| 01/18/2006 | EP1615952A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 |
| 01/18/2006 | EP1615950A2 S. pneumoniae antigens |
| 01/18/2006 | EP1615665A2 Delivery of immune response modifier compounds |
| 01/18/2006 | EP1615664A1 Pharmaceutical composition for treatment of immunological disorders |
| 01/18/2006 | EP1615663A1 Agent for treating leishmania infections |
| 01/18/2006 | EP1615662A1 Transfection of blood cells with mrna for immunostimulation and gene therapy |
| 01/18/2006 | EP1615661A2 Tumor antigens bfa5 for prevention and/or treatment of cancer |
| 01/18/2006 | EP1615614A2 Optimal polyvalent vaccine for cancer |
| 01/18/2006 | EP1615610A2 Inhibitors of coronavirus |
| 01/18/2006 | EP1404672B1 Tyrosine kinase inhibitors |
| 01/18/2006 | EP1278851B1 Humanised antibodies to the epidermal growth factor receptor |
| 01/18/2006 | EP1100925B1 Attenuated equine herpesvirus |
| 01/18/2006 | EP1018548B1 Cellular immunogenicity potentiating composition containing alpha-glycosylceramide |
| 01/18/2006 | EP0994722B1 Method of removing endotoxin from vaccines |
| 01/18/2006 | EP0882129B1 Recombinant expression of s-layer proteins |
| 01/18/2006 | EP0735895B1 A method for preventing or controlling cataract |
| 01/18/2006 | CN1723283A Method for manufacturing recombinant polyclonal proteins |
| 01/18/2006 | CN1723041A Stable immunogenic product comprising antigenic heterocomplexes |
| 01/18/2006 | CN1723040A Amended recombinant cells (ARCs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants |
| 01/18/2006 | CN1723039A Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| 01/18/2006 | CN1723038A Pharmaceutical composition for inducing an immune response in a human or animal |
| 01/18/2006 | CN1723037A Methods and compositions for promoting the maturation of monocytes |
| 01/18/2006 | CN1723032A Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 01/18/2006 | CN1723027A Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 01/18/2006 | CN1722953A Methods for treating cancer by inhibiting Wnt signaling |
| 01/18/2006 | CN1721445A Degraded TPO agonist antibody |
| 01/18/2006 | CN1721444A Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 01/18/2006 | CN1721442A Proteins producing an altered immunogenic response and methods of making and using the same |
| 01/18/2006 | CN1721436A Modified tumor antigen peptide and use thereof |
| 01/18/2006 | CN1720994A Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 01/18/2006 | CN1720992A Treatment for central nervous system lymphoma |
| 01/18/2006 | CN1720991A Degraded agonist antibody |
| 01/18/2006 | CN1720990A Degraded agonist antibody |
| 01/18/2006 | CN1237170C Method of proliferating natural killer cells |
| 01/18/2006 | CN1237076C Polypeptide variants with altered effector function |
| 01/18/2006 | CN1236831C Compositions for protein delivery via the pulmonary route |
| 01/18/2006 | CN1236818C Caprine arthritis-encephalitis virus provided immunoprotection against HIV-1 infection |
| 01/18/2006 | CN1236815C Application of integrin antagonists in preparation of medicine for treating multiple myeloma and myeloma-induced bone resorption |
| 01/18/2006 | CN1236792C Brain active effect matter for prevention and treating encephalopathy and developing intelligence and its preparation method |
| 01/18/2006 | CA2572427A1 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| 01/17/2006 | US6987176 Combinant polypeptide for use in the manufacture of vaccines against Campylobacter induced diarrhea and to reduce colonization |
| 01/17/2006 | US6987171 Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
| 01/17/2006 | US6987168 Tryptase inhibitor proteins derived from blood-feeding anthropod ectoparasites |
| 01/17/2006 | US6987166 Anti-C5a antibodies |
| 01/17/2006 | US6987023 DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
| 01/17/2006 | US6987006 Genetically engineered erythropoietin for diagnosis, prevention and treatment of thrombis, cancer, neovascularization, inflammation and autoimmune diseases |
| 01/17/2006 | US6987005 Where the human SNORF33 receptor has the amino acid sequence SEQ ID NO: 6; encoded by ATCC deposited plasmids; activated by either tyramine, tryptamine, or beta -phenyl-ethylamine; vectors; cells; membranes; nervous system disorders |
| 01/17/2006 | US6986996 Using anti-heparanase antibody to bind heparanase encoded by amino acid sequence no.1 for monitoring heparanase protein expression of heparanase gene in white blood cells in vitro; drug delivery targets; diagnosis of tumors, cancer and metastasis |
| 01/17/2006 | US6986900 biocompatible implants for delivery of pharmaceutically active agents to the posterior segment of the eye; having a scleral surface, an orbital surface, an injection port on the orbital surface, and a fluid conducting passageway |
| 01/17/2006 | US6986894 Methods for the treatment of coagulation disorders with lipoprotein associated coagulation inhibitor (LACI) |
| 01/17/2006 | US6986893 Administering botulinum toxin in order to reduce mucus secretion of patient, wherein mucus secretion is not a symptom of rhinorrhea |
| 01/17/2006 | US6986892 Immunogenic Hepatitis C virus non-structural polypeptides |
| 01/17/2006 | US6986891 Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof |